181 related articles for article (PubMed ID: 27490956)
1. Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.
Czodrowski P; Mallinger A; Wienke D; Esdar C; Pöschke O; Busch M; Rohdich F; Eccles SA; Ortiz-Ruiz MJ; Schneider R; Raynaud FI; Clarke PA; Musil D; Schwarz D; Dale T; Urbahns K; Blagg J; Schiemann K
J Med Chem; 2016 Oct; 59(20):9337-9349. PubMed ID: 27490956
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.
Schiemann K; Mallinger A; Wienke D; Esdar C; Poeschke O; Busch M; Rohdich F; Eccles SA; Schneider R; Raynaud FI; Czodrowski P; Musil D; Schwarz D; Urbahns K; Blagg J
Bioorg Med Chem Lett; 2016 Mar; 26(5):1443-51. PubMed ID: 26852363
[TBL] [Abstract][Full Text] [Related]
3. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
[TBL] [Abstract][Full Text] [Related]
4. New CDK8 inhibitors as potential anti-leukemic agents - Design, synthesis and biological evaluation.
Solum E; Hansen TV; Aesoy R; Herfindal L
Bioorg Med Chem; 2020 May; 28(10):115461. PubMed ID: 32245563
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer.
Xu J; Qi H; Wang Z; Wang L; Steurer B; Cai X; Liu J; Aliper A; Zhang M; Ren F; Zhavoronkov A; Ding X
J Med Chem; 2024 May; 67(10):8161-8171. PubMed ID: 38690856
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.
Lapierre JM; Eathiraj S; Vensel D; Liu Y; Bull CO; Cornell-Kennon S; Iimura S; Kelleher EW; Kizer DE; Koerner S; Makhija S; Matsuda A; Moussa M; Namdev N; Savage RE; Szwaya J; Volckova E; Westlund N; Wu H; Schwartz B
J Med Chem; 2016 Jul; 59(13):6455-69. PubMed ID: 27305487
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening.
Wang T; Yang Z; Zhang Y; Yan W; Wang F; He L; Zhou Y; Chen L
Eur J Med Chem; 2017 Mar; 129():275-286. PubMed ID: 28231524
[TBL] [Abstract][Full Text] [Related]
9. Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors.
Zhang H; Jing L; Liu M; Goto M; Lai F; Liu X; Sheng L; Yang Y; Yang Y; Li Y; Chen X; Lee KH; Xiao Z
Eur J Med Chem; 2021 Nov; 223():113634. PubMed ID: 34147745
[TBL] [Abstract][Full Text] [Related]
10. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
[TBL] [Abstract][Full Text] [Related]
11. Binding patterns and structure-activity relationship of CDK8 inhibitors.
Ma D; Chen X; Shen XB; Sheng LQ; Liu XH
Bioorg Chem; 2020 Mar; 96():103624. PubMed ID: 32078847
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma.
Yuan K; Kuang W; Chen W; Ji M; Min W; Zhu Y; Hou Y; Wang X; Li J; Wang L; Yang P
Eur J Med Chem; 2022 Jan; 228():114024. PubMed ID: 34875521
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antiproliferative activity of imidazo[2,1-b][1,3,4]thiadiazole derivatives.
Kumar S; Gopalakrishnan V; Hegde M; Rana V; Dhepe SS; Ramareddy SA; Leoni A; Locatelli A; Morigi R; Rambaldi M; Srivastava M; Raghavan SC; Karki SS
Bioorg Med Chem Lett; 2014 Oct; 24(19):4682-4688. PubMed ID: 25205189
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
Mallinger A; Schiemann K; Rink C; Stieber F; Calderini M; Crumpler S; Stubbs M; Adeniji-Popoola O; Poeschke O; Busch M; Czodrowski P; Musil D; Schwarz D; Ortiz-Ruiz MJ; Schneider R; Thai C; Valenti M; de Haven Brandon A; Burke R; Workman P; Dale T; Wienke D; Clarke PA; Esdar C; Raynaud FI; Eccles SA; Rohdich F; Blagg J
J Med Chem; 2016 Feb; 59(3):1078-101. PubMed ID: 26796641
[TBL] [Abstract][Full Text] [Related]
16. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics.
Zhang L; Cheng C; Li J; Wang L; Chumanevich AA; Porter DC; Mindich A; Gorbunova S; Roninson IB; Chen M; McInnes C
J Med Chem; 2022 Feb; 65(4):3420-3433. PubMed ID: 35114084
[TBL] [Abstract][Full Text] [Related]
17. Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition.
Chen M; Li J; Liang J; Thompson ZS; Kathrein K; Broude EV; Roninson IB
Cells; 2019 Nov; 8(11):. PubMed ID: 31717492
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Inhibitors of CDK8 for the Treatment of Cancer.
Li Y; Liu Y; Wu J; Liu X; Wang L; Wang J; Yu J; Qi H; Qin L; Ding X; Ren F; Zhavoronkov A
J Med Chem; 2023 Apr; 66(8):5439-5452. PubMed ID: 37029334
[TBL] [Abstract][Full Text] [Related]
19. Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
Zhang L; Zhao J; Zhang B; Lu T; Chen Y
Eur J Med Chem; 2018 Apr; 150():809-816. PubMed ID: 29602036
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and antiproliferative activity of novel heterobivalent hybrids based on imidazo[2,1-b][1,3,4]thiadiazole and imidazo[2,1-b][1,3]thiazole scaffolds.
Romagnoli R; Baraldi PG; Prencipe F; Balzarini J; Liekens S; Estévez F
Eur J Med Chem; 2015 Aug; 101():205-17. PubMed ID: 26141911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
